Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair

Table 3 Radiosensitization effects of YM155 on Eca109 xenograft mouse model

Treatment	Doubling time (days)	Absolute growth delay (days)^a	Normalized growth delay (days)^b	Enhancement factor
Control	5.7 ± 0.5	0
IR	8.0 ± 2.0	2.3 (8.0-5.7)
YM155	9.0 ± 1.6	3.3 (9.0-5.7)
IR + YM155	17.6 ± 6.5	11.9 (17.6-5.7)	8.6 (11.9-3.3)	3.75 (8.6/2.3)

^aAbsolute growth delay, the doubling tumor time of treatment group minus that of control group; ^bNormalized growth delay, the time of absolute growth delay of tumor in IR combined with YM155 group minus that of YM155 group.

ISSN: 1756-8722